Subject: Specialty Quantity Limit Ninlaro 2995-H P2023
Policy:
I. PROGRAM DESCRIPTION
The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.
II. COVERED QUANTITIES
|
Medication
|
Standard Limit
|
FDA-recommended dosing
|
|
Ninlaro (ixazomib) 4 mg capsules
|
3 per 28 days
|
Recommended starting dose of 4 mg taken orally on
days 1, 8, and 15 of a 28-day cycle
Dose reductions due to adverse reactions:
• First reduction to 3 mg
• Second reduction to 2.3 mg
Dose reductions are recommended for adverse
reactions, moderate or severe hepatic impairment
and severe renal impairment.
|
|
Ninlaro (ixazomib) 3 mg capsules
|
3 per 28 days
|
|
Ninlaro (ixazomib) 2.3 mg capsules
|
3 per 28 days
|
Place of Service:
Outpatient
The above policy is based on the following references:
- Ninlaro [package insert]. Lexington, MA: Takeda Pharmaceuticals America, Inc.; May 2022.
Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.
April 17, 2024
